The IHP would still be the ones to make the final recommendations.

Participants are followed weekly for 3 weeks after treatment to screen for adverse events, including IHPS.

It is the IHP that will rule during the next two months what is in or out of scope.

This is the responsibility of the Independent Hearings panel (the IHP) made up of independent experts and chaired by Judge David Kirkpatrick.